Lilly's Commitment to Alzheimer's Research
Alzheimer’s is such a complex disease that our research must be both determined and persistent. Scientists at Eli Lilly and Company have studied the complicated biology of Alzheimer’s disease for over 30 years. Their discoveries have helped shape the development of drugs being researched today. In 2017, Lilly presented findings from nearly 40 studies at the Alzheimer’s Association annual conference.
We now understand more about how Alzheimer’s disease may develop in the brain. We have research studies testing investigational drugs to see whether they may slow or stop the development of Alzheimer’s. What’s more, we are now testing new ways to see changes in the brain. This may help speed up research by helping us to find the right volunteers more quickly.Next Section arrow_downward